Investor Backing & Capital Strength:
Fresh capital arrived via a $50M April 2026 investment from Boehringer Ingelheim alongside an earlier Series C led by Dassault Systèmes/Medidata, extending resources for commercialization. The concurrent transfer of CT‑155 commercialization/marketing rights signals committed funding tied to revenue‑bearing activities.
Strategic Partnerships:
Long‑running collaborations deepened with Boehringer Ingelheim (commercialization rights for CT‑155) and Otsuka (Rejoyn), while Dassault Systèmes/Medidata broadened a technology partnership to support scale‑up. A January 2026 partnership with Ultrahuman expands reach beyond traditional PDT channels.
Product Line Growth:
Recent FDA authorizations for CT‑132 (episodic migraine) and Rejoyn (MDD) broaden the platform and advance the company toward launches. These milestones are highlighted as bolstering credibility for future products.
